All In MedTech

Device Trial Radar · NCT03641300

Efficacy of Convulsive Therapies for Bipolar Depression

Cognitive Outcomes and Response/Remission Efficacy of Convulsive Therapies for Bipolar Depression: the CORRECT-BD Trial

Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

76

Actual

Start

Sep 21, 2018

Primary completion

Mar 4, 2024

Study completion Aug 9, 2024

Sponsor

Lead sponsor
Centre for Addiction and Mental HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of British Columbia; Ontario Shores Centre for Mental Health Sciences; Brain Canada
First posted
Aug 22, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Bipolar Disorder (BD). Research indicates that the prevalence of treatment resistance in bipolar depression is twice that of unipolar depression. The limited effectiveness of current treatments for bipolar depression coupled with the medical and economic burden associated with the disorder engenders a need for novel therapeutic interventions that can provide greater response and remission rates.

Conditions

  • Bipolar Disorder
  • Bipolar Depression
  • Bipolar I Disorder
  • Bipolar II Disorder

Interventions

  • Magnetic Seizure Therapy (MST)Device

    MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds). This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.

  • Electroconvulsive Therapy (ECT)Device

    In the ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Remission (score </= 10) on the Hamilton Rating Scale for Depression - 24 (HRSD-24)Time frame: Greater than 8 treatments (2.5 weeks)
  2. Cognitive adverse effects as indexed by the Autobiographical Memory Test (AMT)Time frame: Greater than 8 treatments (2.5 weeks)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • UBC Hospital, University of British Columbia (UBC)

    Vancouver, British Columbia, Canada

  • Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health

    Toronto, Ontario, Canada

  • Ontario Shores Centre for Mental Health Sciences

    Whitby, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.